Humoral anti-SARS-CoV-2 immune response after two doses of Comirnaty vaccine in nursing home residents by previous infection status.
COVID-19
Humoral vaccine response
SARS-CoV-2
Serological assay
Journal
Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899
Informations de publication
Date de publication:
24 01 2022
24 01 2022
Historique:
received:
30
06
2021
revised:
18
10
2021
accepted:
28
11
2021
pubmed:
12
12
2021
medline:
18
1
2022
entrez:
11
12
2021
Statut:
ppublish
Résumé
Coronavirus disease 2019 (COVID-19) is associated with increased morbidity and mortality in older adults. Although the advent of the first vaccines has significantly reduced these rates, data on older adults in clinical trials are scarce. We quantified and compared the humoral response in individuals with vs. without pre-existing seropositivity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), in a cohort of 69 patients living in a nursing home and who had received the recommended two doses of the Comirnaty (Pfizer-BioNTech®) vaccine. All 69 patients (100%) tested positive for antibodies against SARS-CoV-2 at 2 months post-vaccination. Residents with a pre-vaccination infection had significantly higher titers of anti-spike 1 IgG than those with no prior infection (median [interquartile range]: 55,726 [14463-78852] vs. 1314 [272-1249] arbitrary units, respectively; p < 0.001). The same result was observed for neutralizing antibodies titers (704 [320-1280] vs. 47 [20-40] respectively; p < 0.001). Between the pre-vaccination and post-vaccination periods, for IgG and neutralizing antibodies, we observed a 49 and 8-fold increase respectively. In comparison to the wild-type Receptor Binding Domain (RBD), the binding capacity of these vaccine sera was significantly decreased on the B.1.351 and P.1 variants RBD but not decreased with respect to the B.1.1.7 RBD. Although all nursing home residents developed a humoral response following Comirnaty vaccine, its intensity appeared to depend on the pre-vaccination serological status. Our results raise the question of how many doses of vaccine should be administered in older and how long the protection will be effective.
Sections du résumé
BACKGROUND
Coronavirus disease 2019 (COVID-19) is associated with increased morbidity and mortality in older adults. Although the advent of the first vaccines has significantly reduced these rates, data on older adults in clinical trials are scarce.
OBJECTIVES
We quantified and compared the humoral response in individuals with vs. without pre-existing seropositivity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), in a cohort of 69 patients living in a nursing home and who had received the recommended two doses of the Comirnaty (Pfizer-BioNTech®) vaccine.
RESULTS
All 69 patients (100%) tested positive for antibodies against SARS-CoV-2 at 2 months post-vaccination. Residents with a pre-vaccination infection had significantly higher titers of anti-spike 1 IgG than those with no prior infection (median [interquartile range]: 55,726 [14463-78852] vs. 1314 [272-1249] arbitrary units, respectively; p < 0.001). The same result was observed for neutralizing antibodies titers (704 [320-1280] vs. 47 [20-40] respectively; p < 0.001). Between the pre-vaccination and post-vaccination periods, for IgG and neutralizing antibodies, we observed a 49 and 8-fold increase respectively. In comparison to the wild-type Receptor Binding Domain (RBD), the binding capacity of these vaccine sera was significantly decreased on the B.1.351 and P.1 variants RBD but not decreased with respect to the B.1.1.7 RBD. Although all nursing home residents developed a humoral response following Comirnaty vaccine, its intensity appeared to depend on the pre-vaccination serological status.
CONCLUSION
Our results raise the question of how many doses of vaccine should be administered in older and how long the protection will be effective.
Identifiants
pubmed: 34893341
pii: S0264-410X(21)01558-9
doi: 10.1016/j.vaccine.2021.11.086
pmc: PMC8639399
pii:
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
COVID-19 Vaccines
0
Spike Glycoprotein, Coronavirus
0
Vaccines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
531-535Informations de copyright
Copyright © 2021 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Front Microbiol. 2020 Oct 19;11:584251
pubmed: 33193227
J Clin Virol. 2020 Sep;130:104569
pubmed: 32769023
JAMA. 2021 Apr 13;325(14):1467-1469
pubmed: 33646292
Lancet. 2021 Mar 20;397(10279):1057-1058
pubmed: 33640038
Nature. 2020 Aug;584(7821):450-456
pubmed: 32698192
Science. 2021 Apr 23;372(6540):354-355
pubmed: 33888633
J Clin Med. 2021 Apr 21;10(9):
pubmed: 33919328
N Engl J Med. 2021 Apr 8;384(14):1372-1374
pubmed: 33691060
Am J Transplant. 2021 Aug;21(8):2719-2726
pubmed: 33866672
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
EClinicalMedicine. 2021 Feb;32:100734
pubmed: 33589882
Nature. 2021 Feb;590(7844):140-145
pubmed: 33137809
Geroscience. 2021 Feb;43(1):31-51
pubmed: 33569701
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
Rev Med Virol. 2017 Nov;27(6):
pubmed: 28905444
Nature. 2020 Oct;586(7830):516-527
pubmed: 32967006
JAMA. 2021 May 4;325(17):1784-1786
pubmed: 33720292
Science. 2021 Mar 25;:
pubmed: 33766944
Kidney Int. 2021 Jun;99(6):1498-1500
pubmed: 33887315
Sci Immunol. 2021 Apr 15;6(58):
pubmed: 33858945